Table 4

Response to induction chemotherapy
Assessment parameter Number of patients (%),N =18
Clinicoradiologic assessment after first cycle of induction chemotherapy HPV- HPV+ all patients
N =15 N = 3 N =18
CR 1 (7) 1 (33) 2 (11)
PR 11 (73) 2 (67) 13 (72)
SD 2 (13) 2 (11)
PD 1 1 (6)
Clinicoradiologic assessment after third cycle of induction chemotherapy
CR 3 (25)
PR 9 (75)
Histopathologic result 1 cycle 3 cycles all patients
pCR of primary tumor 1 (6) 8 (44) 9 (50)
pCR of neck metastasis* 2 (14) 4 (29) 6 (33)
pCR of primary and neck* 1 (7) 4 (29) 5 (27)
Histopathologic result level 0 level -1 all patients
N =12 N = 6 N =18
pCR of primary tumor 6 (50) 3 (50) 9 (50)
pCR of neck metastasis* 5 (42) 1 (17) 6 (33)
pCR of primary and neck* 4 (33) 1 (17) 5 (27)
yTNM  HPV- HPV+ all patients
N =15 N = 3 N =18
ypT0ypN0 3 (20) 3 (100) 6 (33)
ypT0ypN1 1 (7) 1 (6)
ypT0ypN2 2 (13) 2 (11)
ypT1ypN0 2 (13) 2 (11)
ypT1ypN1 2 (13) 2 (11)
ypT1ypN2 1 (7) 1 (6)
ypT2ypN2 1 (7) 1 (6)
ypT3ypN0 1 (7) 1 (6)
ypT4ypN0 1 (7) 1 (6)
ypT4ypN2 1 (7) 1 (6)
Histopathologic risk classification
Low risk 14 (78)
High risk 4 (22)

*4 patients presented with cN0, therefore only 14 patients went into this calculation (in level 0: 1 patient; in level −1: 3 patients).

Oertel et al.

Oertel et al. BMC Cancer 2012 12:483   doi:10.1186/1471-2407-12-483

Open Data